Insights into Catheter Ablation of Ventricular Tachycardias in Arrhythmogenic Right Ventricular Cardiomyopathy / Dysplasia

Authors

  • Sokratis Pastromas Henry Dunant Hospital, Athens, Greece
  • Emmanuel Koutalas Department of Electrophysiology, Heart Center, Leipzig, Germany

Keywords:

sudden cardiac death, arrhythmogenic right ventricular cardiomyopathy/dysplasia, ventricular tachycardia/fibrillation, implantable cardioverter defibrillator, catheter ablation/mapping

Abstract

Arrhythmogenic right ventricular cardiomyopathy/ dysplasia (ARVC/D), mostly affecting young/middle-aged individuals, poses a significant risk of malignant ventricular arrhythmias (VAs) and subsequent sudden cardiac death (SCD). Antiarrhythmic agents (AAA) provide insufficient arrhythmia suppression and prevention and can be proarrhythmic. Thus, the implantable cardioverter-defibrillator (ICD) is considered the first-line treatment, especially in patients with secondary prevention indication. Nevertheless, catheter ablation is an additional therapy to the ICD which has proved its efficacy in primary and secondary prevention of fatal arrhythmias and sudden cardiac death. The superiority of the combined endo- and epicardial VT ablation in this population is clear since ARVC/D substrate has been shown to be mostly epicardial. Due to progressive nature of ARVC/D, ablation seems to be a useful tool for the patients who experience recurrent VT episodes or electrical storms.

Downloads

Download data is not yet available.

Downloads

Published

2016-03-04

Issue

Section

Review

How to Cite

Insights into Catheter Ablation of Ventricular Tachycardias in Arrhythmogenic Right Ventricular Cardiomyopathy / Dysplasia. (2016). Rhythmos, 10(4), 80-86. https://www.rhythmos.gr/index.php/Rhythmos/article/view/171

Similar Articles

1-10 of 225

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 1 2 3 4 > >>